Klivira
Request demo

Streamlining Fertility (REI) Biologics Prior Auth Workflows

Navigating **fertility (REI) biologics prior auth** requires precision and deep understanding of both clinical protocols and payer requirements. Klivira automates this complex process, ensuring timely access to critical treatments for reproductive endocrinology patients.

Reproductive endocrinology and infertility (REI) practices face unique challenges in securing prior authorizations for high-cost specialty drugs, particularly biologics. The administrative burden associated with managing indication-specific criteria, step therapy, and re-authorization cycles can significantly impact patient care timelines and revenue cycles. Klivira provides a specialized solution to mitigate these challenges.

The Complex Landscape of Fertility (REI) Biologics Prior Auth

Biologics, including TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, are often prescribed for co-morbid autoimmune conditions like rheumatoid arthritis or inflammatory bowel disease that can impact fertility and pregnancy outcomes. Securing prior authorization for these high-cost specialty drugs, alongside fertility specialty drugs and procedures such as IVF and fertility preservation, adds significant administrative complexity for REI practices.

Key Prior Authorization Triggers for Biologics in Reproductive Health

Prior authorization for biologics in fertility patients is typically triggered by several critical factors. These include stringent indication-specific criteria, adherence to step therapy requirements (e.g., failure of conventional therapies), payer mandates for biosimilar substitution, and comprehensive screening documentation for conditions like TB and hepatitis, which are vital considerations for patients undergoing fertility treatments.

Klivira's Automated Workflow for Fertility Biologics PA

  • **Indication Classification:** Identifies underlying autoimmune or inflammatory conditions (e.g., Crohn's, RA) from EMR diagnoses, alongside fertility-specific diagnoses, to align with payer medical policies.
  • **Step Therapy Automation:** Verifies prior-line therapy history (e.g., csDMARDs for rheumatology, 5-ASA for IBD) to fulfill step therapy requirements for biologics impacting fertility patients.
  • **Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, ensuring compliance with preferred formularies for biologic agents used in the fertility cohort.
  • **Screening Documentation:** Extracts and validates necessary screening results (TB, hepatitis B/C, immunization status) from FHIR data, crucial for biologics and pregnancy planning.
  • **Periodic Re-authorization:** Manages typical 6/12-month re-authorization cycles for chronic biologic use, integrating continuous disease-activity and response documentation.
  • **Medical-vs-Pharmacy Benefit Routing:** Automatically routes PA requests based on whether the biologic is covered under the medical or pharmacy benefit, depending on administration mode.

EMR Integration and Payer Connectivity for REI Practices

Klivira integrates seamlessly with leading EMR systems via standards like SMART on FHIR, enabling automated extraction of clinical data relevant to fertility patients, including diagnoses, lab results, and medication history. This data fuels efficient submission of biologics PA requests through various payer channels, including X12 278 transactions, ePA platforms, and direct payer portal connectivity, reducing manual effort for your team.

Ensuring Evidence-Based Prior Authorization for Fertility Patients

Our platform aligns with evidence-based criteria for biologics, drawing upon comprehensive policy libraries to support PA decisions for conditions relevant to fertility patients. By automating the collection and submission of required clinical documentation, Klivira helps ensure that prior authorization requests for high-cost biologic therapies are complete, accurate, and aligned with payer guidelines, reducing the risk of denials and delays.

Frequently asked questions

How does Klivira handle step therapy requirements for biologics in fertility patients?

Klivira's workflow automates the verification of prior-line therapy history, such as conventional DMARDs for rheumatologic conditions or 5-ASA for IBD, directly from EMR data. This ensures that all step therapy requirements for biologics are met and documented before submission, streamlining the prior authorization process for fertility patients.

Can Klivira integrate with our EMR to pull documentation for fertility biologics PA?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This allows our platform to automatically extract relevant clinical data, including diagnoses, lab results (e.g., TB, hepatitis screenings), and medication history, directly from patient charts to support biologics prior authorization requests for fertility patients.

What about biosimilar substitution policies for fertility-related biologics?

Klivira's system incorporates per-payer biosimilar substitution policies into its routing logic. This ensures that prior authorization requests for biologics used in fertility cohorts comply with specific payer mandates regarding preferred biosimilars, minimizing delays and potential denials related to formulary adherence.

How does Klivira manage re-authorizations for chronic biologic use during fertility treatment?

Our platform automates the management of periodic re-authorization cycles, typically every 6 or 12 months, for chronic biologic therapies. Klivira integrates continuous disease-activity and response documentation from the EMR, ensuring all necessary criteria are met for ongoing approval without disrupting fertility treatment plans.

Does Klivira support both pharmacy and medical benefit biologics for fertility patients?

Yes, Klivira's system is designed to handle biologics covered under both pharmacy and medical benefits. It intelligently routes prior authorization requests based on the administration mode and payer rules, ensuring that the correct benefit channel is utilized for all biologics prescribed to fertility patients.

Related coverage

Other fertility-reproductive prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo